Companion Animal Pharmaceuticals Market Report 2026

Companion Animal Pharmaceuticals Market Overview

• Companion Animal Pharmaceuticals market size has reached to $17.85 billion in 2025 • Expected to grow to $29.14 billion in 2030 at a compound annual growth rate (CAGR) of 10.3% • Growth Driver: Growing Prevalence Of Zoonotic Diseases Fuels Growth Of Companion Animal Pharmaceuticals Market • Market Trend: Innovation Product Launches To Meet The Demand • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Companion Animal Pharmaceuticals Market?

Companion animal pharmaceuticals refer to the pharmaceutical medication process in which animal pharmacists insist on medications, fill prescriptions, and manage drug therapies for animals. It is used in the diagnosis, mitigation, and treatment of different animal diseases. The main types of companion animal pharmaceuticals are dogs, cats, horses, and other companion animals. Dogs refer to a highly variable carnivorous domesticated mammal of the genus closely related to the common wolf. The indications are infectious diseases, dermatologic diseases, pain, orthopedic diseases, behavioral diseases, and other indications, which are sold through multiple distribution channels, involved veterinary hospitals, veterinary clinics, and retail pharmacies.

What Is The Companion Animal Pharmaceuticals Market Growth Forecast?

The companion animal pharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $29.14 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to advancements in precision medicine for companion animals, increasing adoption of digital prescription management, growth in preventive healthcare and vaccination programs, rising demand for specialized behavioral and orthopedic therapeutics, expansion of veterinary retail pharmacy networks. Major trends in the forecast period include increasing demand for companion animal vaccines, rising adoption of anti-inflammatory and pain management drugs, growth in behavioral and dermatologic therapeutics, expansion of veterinary retail pharmacies and clinics, customization of drug formulations for specific companion animals.

Global Companion Animal Pharmaceuticals Market Segmentation

1) By Product Type: Therapeutic Drugs, Vaccines, Other Product Types 2) By Animal Type: Dogs, Cats, Equines, Other Animal Types 3) By Route Of Administration: Oral, Injectable, Topical, Inhalation, Other Route Of Administrations 4) By Distribution Channel: Veterinary Hospitals And Clinics, Retail Pharmacies, Online Pharmacies Or E Commerce, Veterinary Distributors, Direct Sales 5) By End User: Veterinarians, Pet Owners, Animal Care Centers, Pet Specialty Stores Subsegments: 1) By Therapeutic Drugs: Anti infectives, Cardiovascular Drugs, Hormonal And Metabolic Drugs, Dermatological Drugs, Pain Relief And Anti Inflammatory Drugs, Gastrointestinal Drugs, Respiratory Drugs, Central Nervous System (CNS) Drugs 2) By Vaccines: Bacterial Vaccines, Viral Vaccines, Combination Vaccines 3) By Other Product Types: Nutraceuticals And Supplements, Specialty Pharmaceuticals

What Is The Driver Of The Companion Animal Pharmaceuticals Market?

The growing prevalence of zoonotic diseases is expected to propel the growth of the companion animal pharmaceuticals market going forward. A zoonotic illness is a disease that can be naturally transferred from vertebrate animals to humans or from people to vertebrate animals. Zoonotic diseases are rising due to increased human animal interactions, which create more opportunities for pathogens to jump from animals to humans, accelerating the spread of infections. Companion Animal Pharmaceuticals help control zoonotic diseases by providing medications and preventive treatments that reduce infections in pets, thereby lowering the risk of transmission to humans. For instance, in February 2023, according to the Council on Foreign Relations (CFR), a US-based independent, nonpartisan member organization, think tank, and publisher, up to 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases have zoonotic origins. Worldwide, zoonoses cause 2.7 million human fatalities and 2.5 billion episodes of disease in people each year. Therefore, the growing prevalence of zoonotic diseases is driving the growth of the companion animal pharmaceuticals industry.

Key Players In The Global Companion Animal Pharmaceuticals Market

Major companies operating in the companion animal pharmaceuticals market are Elanco Animal Health Incorporated, Boehringer Ingelheim International GmbH, Ceva Santé Animale, Inovet Group, Merck & Co. Inc., Norbrook Laboratories Ltd., Vetoquinol S.A., Virbac S.A., Zoetis Inc., Eli Lilly and Company, IDEXX Laboratories Inc., Merial Limited, Dechra Pharmaceuticals PLC, Aratana Therapeutics Inc., Kindred Biosciences Inc., Jaguar Health Inc., Nexvet Biopharma PLC, PetMed Express Inc., Heska Corporation, Synbiotics Corporation, Eurovet Animal Health B.V., Abaxis Inc., Putney Inc.

Global Companion Animal Pharmaceuticals Market Trends and Insights

Major companies operating in the companion animal pharmaceutical market are launching innovative products, such as oral flea and tick products, to meet larger customer bases, more sales, and increase revenue. Oral flea and tick products refer to medications that are given by mouth to prevent or treat flea and tick infestations in pets. For instance in October 2024, Elanco Animal Health Incorporated, a US-based pharmaceutical company, announced FDA approval for Credelio Quattro, a new chewable parasiticide designed for dogs. This product offers monthly protection against six types of parasites, including fleas, ticks, and several internal worms. With Credelio Quattro, Elanco aims to provide a convenient, comprehensive solution for pet owners seeking broad-spectrum parasite control. This launch highlights Elanco's commitment to meeting the growing demand for innovative and effective pet health solutions.

What Are Latest Mergers And Acquisitions In The Companion Animal Pharmaceuticals Market?

In July 2024, Dechra Pharmaceuticals Limited, a UK based provider of veterinary pharmaceuticals and related health products for companion animals and livestock, acquired Invetx Inc. for an undisclosed amount. With this acquisition, Dechra expanded its companion animal pharmaceuticals portfolio and strengthened its foothold in high growth biologics by adding innovative monoclonal antibody therapeutics targeting chronic conditions in cats and dogs. Invetx Inc. is a US based provider of protein based therapeutic biologics for companion animals, specializing in the discovery, development, and manufacturing of species specific monoclonal antibody treatments.

Regional Outlook

North America was the largest region in the companion animal pharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the companion animal pharmaceuticals market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Companion Animal Pharmaceuticals Market?

The companion animal pharmaceuticals market includes revenues earned by entities by providing veterinary pharmaceuticals, vaccines, and health management tools. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.